Kristin Larsen, Horace Spencer, Meera Mohan, Clyde Bailey, Kerri Hill, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Amani Erra, Angel A Mitma, Pankaj Mathur, Lakshmi Yarlagadda, Sravani Gundarlapalli, Yetunde Ogunsesan, Munawwar Hussain, Nishanth Thalambedu, Jaskirat Sehti, Samer Al Hadidi, Sharmilan Thanendrarajan, Monica Graziutti, Maurizio Zangari, Bart Barlogie, Frits van Rhee, Guido Tricot, Carolina Schinke
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most patients in the US undergoing inpatient ASCT. Furthermore, hospitalization rates for patients that undergo outpatient ASCT remain high. Adequate markers that predict hospitalization during outpatient ASCT are lacking, yet would be of great clinical value to select patients that are suited to outpatient ASCT...
March 16, 2022: Journal of Clinical Medicine